Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
Jonathan A. Ledermann(University College London), Philipp Harter(Kliniken Essen-Mitte), Charlie Gourley(Edinburgh Cancer Research), Michael Friedländer(Prince of Wales Hospital), Ignace Vergote(KU Leuven), Gordon Rustin(Mount Vernon Hospital), Clare L. Scott(The Royal Melbourne Hospital), Werner Meier(Evangelisches Krankenhaus Düsseldorf), Ronnie Shapira‐Frommer(Sheba Medical Center), Tamar Safra(Tel Aviv Sourasky Medical Center), Daniela Matei(Northwestern University), Anitra Fielding(AstraZeneca (United Kingdom)), Stuart Spencer(AstraZeneca (United Kingdom)), Philip Rowe(AstraZeneca (United Kingdom)), Elizabeth Lowe(AstraZeneca (United States)), Darren Hodgson(AstraZeneca (United Kingdom)), Mika A. Sovak(AstraZeneca (United States)), Ursula A. Matulonis(Dana-Farber Cancer Institute)
Cited by 452Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis